The appraisal committee has prepared final draft guidance (FDG) on elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after endocrine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback